Comparable Daughter Radionuclide Redistribution with Superior Tumor Absorbed Dose of the SSTR2 Antagonist [ 225 Ac]Ac-SSO110 Versus [ 225 Ac]Ac-DOTATATE
Journal of Nuclear Medicine · 12.11.2026 · jnumed.126.272589
DOI: 10.2967/jnumed.126.272589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 12.11.2026. Verfasst von Prachi Desai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ariceum Therapeutics GmbH, Berlin, Germany. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
It has been hypothesized that effective cellular internalization is required for the retention of 225Ac daughter radionuclides. Both the complex decay chain of 225Ac and the recoil-mediated release of daughters, particularly 213Bi (half-life, 46 min), raise concerns about redistribution that may reduce tumor absorbed dose (TAD) and increase off-target radiation exposure. Because somatostatin receptor subtype 2 antagonists, such as satoreotide tetraxetan (SSO110, also known as DOTA-JR11), are not internalized, it has been proposed that the daughter radionuclides are less effectively retained compared with internalizing agonists, such as DOTATATE. In this study, we performed a direct and quantitative comparison of daughter radionuclide redistribution after administration of [225Ac]Ac-SSO110 and [225Ac]Ac-DOTATATE.
Methods
Biodistribution and 213Bi redistribution were evaluated in BALB/c nude mice bearing NCI-H69 small cell lung cancer xenografts. Repeated γ-counting combined with biexponential modeling was used to quantify 225Ac and 213Bi activity in tumors, blood, bone marrow, kidneys, the liver, and the intestines up to 96 h postinjection. TAD was calculated with and without accounting for experimentally derived 213Bi redistribution. Real-time in vitro binding assays were conducted to characterize cellular retention of [225Ac]Ac-SSO110. Results: [225Ac]Ac-SSO110 demonstrated higher tumor uptake and prolonged retention compared with [225Ac]Ac-DOTATATE. Redistribution of 213Bi from tumors was minimal and comparable between the agonist and antagonist and reduced the TAD by 4.5% for [225Ac]Ac-SSO110 and 3.9% for [225Ac]Ac-DOTATATE. After accounting for this redistribution, [225Ac]Ac-SSO110 delivered a 2.8-fold higher TAD and a 1.8-fold higher tumor-to-kidney absorbed dose (AD) ratio compared with [225Ac]Ac-DOTATATE. Moreover, 213Bi redistribution had no relevant impact on AD estimates in evaluated healthy organs, including the kidneys, the intestines, blood, and bone marrow. Real-time binding studies demonstrated a sustained cell-associated β--signal after incubation with [225Ac]Ac-SSO110.
Conclusion
Despite negligible internalization, [225Ac]Ac-SSO110 did not show increased macroscopic 213Bi redistribution compared with the internalizing agonist [225Ac]Ac-DOTATATE. Redistribution was limited for both radiopeptides and had only a minor effect on AD estimates for tumors and the evaluated healthy tissues. [225Ac]Ac-SSO110 achieved a higher TAD and more favorable tumor-to-kidney ratio compared with [225Ac]Ac-DOTATATE. Overall, these findings support further evaluation of antagonist-based 225Ac radiopharmaceutical therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ariceum Therapeutics GmbH, Berlin, Germany.
- BRS Berlin Radiopharm Solutions GmbH, Berlin, Germany.
- Oniris, Nantes, France.
- Alpha & Gray, Nantes, France.
- Nantes Université, Université d'Angers, INSERM, CRCI2NA, Nantes, France; and.
- Ariceum International AG, Basel, Switzerland.
Zitieren
APA
Desai, P., Chouin, N., Huber, M., Mewis, D., Sturzbecher-Hoehne, M., Gericke, G., & Jaekel, A. (2026). Comparable Daughter Radionuclide Redistribution with Superior Tumor Absorbed Dose of the SSTR2 Antagonist [ 225 Ac]Ac-SSO110 Versus [ 225 Ac]Ac-DOTATATE. Journal of Nuclear Medicine, jnumed.126.272589. https://doi.org/10.2967/jnumed.126.272589
Vancouver
Desai P, Chouin N, Huber M, Mewis D, Sturzbecher-Hoehne M, Gericke G, et al. Comparable Daughter Radionuclide Redistribution with Superior Tumor Absorbed Dose of the SSTR2 Antagonist [ 225 Ac]Ac-SSO110 Versus [ 225 Ac]Ac-DOTATATE. Journal of Nuclear Medicine. 2026:jnumed.126.272589. doi:10.2967/jnumed.126.272589
BibTeX
@article{Desai2026,
author = {Desai, Prachi and Chouin, Nicolas and Huber, Marion and Mewis, Dennis and Sturzbecher-Hoehne, Manuel and Gericke, Germo and Jaekel, Anika},
title = {Comparable Daughter Radionuclide Redistribution with Superior Tumor Absorbed Dose of the SSTR2 Antagonist [ 225 Ac]Ac-SSO110 Versus [ 225 Ac]Ac-DOTATATE},
journal = {Journal of Nuclear Medicine},
year = {2026},
pages = {jnumed.126.272589},
doi = {10.2967/jnumed.126.272589}
}
EUVIMED